Treatment of patients with heartburn without endoscopic evaluation: On-demand treatment after effective continuous administration of lansoprazole 15 mg

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 7, 2005, Pages 635-643

  Bigard, M A ^a   Genestin, E ^b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b Laboratoires Takeda   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPY; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 26244460778     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02637.x     Document Type: Article

References (21)

1. Spechler SJ. Epidemiology and natural history of gastroesophageal reflux disease. Digestion 1992; 51: 24-9.
2. Heading RC. Review article: diagnosis and clinical investigation of gastro-esophageal reflux disease: a European view. Aliment Pharmacol Ther 2004; 20: 9-13.
3. Glise H, Hallerback B, Wiklund I. Quality of life: a reflection of symptoms and concerns. Scand J Gastroenterol Suppl 1996; 221: 14-7.
4. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001; 23: 998-1017.
5. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
6. Carlsson R, Dent J, Watts R, et al. Gastro-esophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10: 119-24.
7. Bardhan KD. Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98: S40-8.
8. Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999; 49: 451-3.
9. Rubin GP, Contractor B, Bramble MG. The use of long-term acid-suppression therapy. Br J Clin Pract 1995; 49: 119-20.
10. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907-14.
11. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-esophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347-54.
12. Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-esophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002; 14: 857-63.
13. Bytzer P, Blum A, De Herdt D, Dubois D, The Trial Investigators. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004; 20: 181-8.
14. Tsai HH, Chapman R, Shepherd A, et al. and COMMAND Study Group. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastroesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther 2004; 20: 657-65.
15. Sjöstedt S, Befrits R, Sylvan A, et al. On demand versus continuous treatment with esomeprazole (ESO) 20 mg once daily in subjects with healed erosive esophagitis (EE) after initial healing with ESO 40 mg once daily. An open randomized, Swedish multicenter study. Gut 2004; 53: A68.
16. Bour B, Chousterman M, Labayle D, et al. On-demand maintenance therapy with rabeprazole (RAB) 10 mg: an effective alternative to continuous therapy for patients with frequent gastroesophageal reflux symptomatic relapse. Gastroenterology 2003; 124: S1601.
17. Janssen W, Meier E, Gatz G, Pfaffenberger B. On-demand therapy with pantoprazole 20 mg as an effective and safe alternative for the long-term management of patients suffering from mild GERD. Gut 2003; 52: A127.
18. Cooper A.L, Baxter G. Efficacy of lansoprazole on-demand therapy in the treatment of non erosive reflux disease and functional ulcer like dyspepsia. Gut 2003; 52: A137.
19. Kaspari S, Kupcinskas L, Fisher R, Berghoefer P. Effective long-term management of patients suffering from mild GERD with on-demand therapy. Gut 2003; 52: A126.
20. Scholten T, Gatz G, Sander P. On-demand therapy with pantoprazole 20 mg od for the long-term management of GERD patients previously healed from heartburn. Gut 2001; 49: A64.
21. Ponce J, Arguello L, Bastida G, Ponce M, Ortiz V, Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci 2004; 49: 931-6.